Anna Maria Baldelli
Overview
Explore the profile of Anna Maria Baldelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
192
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gagno S, Dandrea M, Mansutti M, Zanusso C, Puglisi F, Dreussi E, et al.
Clin Breast Cancer
. 2018 Dec;
19(2):137-145.e4.
PMID: 30584056
Introduction: Approximately 50% of locally advanced or metastatic breast cancer (MBC) patients treated with first-line exemestane do not show objective response and currently there are no reliable biomarkers to predict...
2.
Rossi D, Giordani P, Alessandroni P, Catalano V, Casadei V, Baldelli A, et al.
World J Oncol
. 2017 Nov;
3(1):39-41.
PMID: 29147277
In this case report we describe the case of a patient with multiple bone metastases of NSCLC, adenocarcinoma with exon 21 point-mutation of EGFR, treated with gefitinib. After only 3...
3.
Catalano V, Bisonni R, Graziano F, Giordani P, Alessandroni P, Baldelli A, et al.
Gastric Cancer
. 2012 Oct;
16(3):411-9.
PMID: 23065042
Background: Elderly patients are generally underrepresented in the study populations of combination chemotherapy trials. This study evaluates the efficacy and safety of a modified FOLFOX regimen in elderly patients with...
4.
Catalano V, Vincenzi B, Giordani P, Graziano F, Santini D, Baldelli A, et al.
Gastric Cancer
. 2012 Jan;
15(4):419-26.
PMID: 22237659
Background: The combination of docetaxel, cisplatin, and 5-fluorouracil (5-FU) has demonstrated a survival advantage over cisplatin and 5-FU, but with substantial hematological toxicity. We aimed to evaluate the efficacy and...
5.
Catalano V, Mellone P, DAvino A, Shridhar V, Staccioli M, Graziano F, et al.
Histopathology
. 2011 Mar;
58(5):669-78.
PMID: 21447133
Aims: HtrA1 is a member of the HtrA (high-temperature requirement factor A) family of serine proteases. HtrA1 plays a protective role in various malignancies due to its tumour suppressive properties....
6.
Rossi D, Dennetta D, Ugolini M, Catalano V, Alessandroni P, Giordani P, et al.
Target Oncol
. 2010 Oct;
5(4):231-5.
PMID: 20890670
Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Efficacy of this drug was documented in the BR.21 trial showing that adenocarcinoma, female gender, Asian ethnicity and never-smoker...
7.
Rossi D, Baldelli A, Catalano V, Casadei V, Alessandroni P, Giordani P, et al.
Breast Cancer
. 2009 Sep;
19(3):275-7.
PMID: 19756926
Visceral metastases of breast cancer have been commonly treated with "aggressive" anthracyclines/taxanes-based chemotherapy. In contrast, this case report concerns an elderly patient with advanced breast cancer (pleural effusion, peritoneal carcinosis,...
8.
Rossi D, Dennetta D, Ugolini M, Alessandroni P, Catalano V, Luzi Fedeli S, et al.
Clin Lung Cancer
. 2008 Oct;
9(5):280-4.
PMID: 18824450
Purpose: Paclitaxel and platinum-based chemotherapy is considered to be a standard approach for locally advanced and metastatic non-small-cell lung cancer (NSCLC). In recent years, weekly paclitaxel has been widely used...
9.
Rossi D, Baldelli A, Casadei V, Luzi Fedeli S, Alessandroni P, Catalano V, et al.
Anticancer Drugs
. 2008 Jul;
19(7):733-7.
PMID: 18594216
To determine the activity and safety of a schedule with a low dose of pegylated liposomal doxorubicin (PLD) and weekly paclitaxel in operable and locally advanced breast cancer patients. Thirty-five...
10.
Rossi D, Alessandroni P, Catalano V, Giordani P, Fedeli S, Fedeli A, et al.
Clin Breast Cancer
. 2008 Feb;
7(11):857-60.
PMID: 18269775
Purpose: Capecitabine is an orally administered precursor of 5'-deoxy-5-fluorouridine that was rationally designed to generate 5-fluorouracil (5-FU) preferentially in tumor tissue. The drug enables chronic dosing that mimics continuous infusion...